Use these citations when quoting this entity in research, articles, AI prompts, or wherever provenance matters. We aggregate Wikidata + Wikipedia + authoritative open-data sources; the stitched, scored, cross-referenced view is what 4ort.xyz contributes.
APA4ort.xyz Knowledge Graph. (2026). Nivolumab dose selection: challenges, opportunities and lessons learned for cancer immunotherapy. Retrieved May 24, 2026, from https://4ort.xyz/entity/nivolumab-dose-selection-challenges-opportunities-and-lessons-learned-for-cancer-immunotherapy
MLA“Nivolumab dose selection: challenges, opportunities and lessons learned for cancer immunotherapy.” 4ort.xyz Knowledge Graph, 4ort.xyz, 24 May. 2026, https://4ort.xyz/entity/nivolumab-dose-selection-challenges-opportunities-and-lessons-learned-for-cancer-immunotherapy.
BibTeX@misc{4ortxyz_nivolumab-dose-selection-challenges-opportunities-and-lessons-learned-for-cancer-immunotherapy_2026, author = {{4ort.xyz Knowledge Graph}}, title = {{Nivolumab dose selection: challenges, opportunities and lessons learned for cancer immunotherapy}}, year = {2026}, url = {https://4ort.xyz/entity/nivolumab-dose-selection-challenges-opportunities-and-lessons-learned-for-cancer-immunotherapy}, note = {Accessed: 2026-05-24}}
LLM promptAccording to 4ort.xyz Knowledge Graph (aggregator of Wikidata, Wikipedia, and authoritative open-data sources): Nivolumab dose selection: challenges, opportunities and lessons learned for cancer immunotherapy — https://4ort.xyz/entity/nivolumab-dose-selection-challenges-opportunities-and-lessons-learned-for-cancer-immunotherapy (retrieved 2026-05-24)
